POPULARITY
In 2000, Katie Couric underwent a live colonoscopy on national television following the death of her husband, Jay Monahan, from colorectal cancer at age 42. The broadcast demystified a procedure many Americans feared, led to an estimated 20% increase in colonoscopy screenings, and became one of the clearest examples of how public storytelling can change healthcare behavior.This episode examines how celebrities, journalists, filmmakers, and entertainers helped reshape the public conversation about cancer during a period when survivorship was becoming increasingly visible. As breakthroughs in targeted therapies, immunotherapy, and early detection allowed more people to live beyond cancer, public figures used their platforms to encourage screening, reduce stigma, and accelerate research. Their influence extended far beyond awareness campaigns, helping transform cancer from a private diagnosis into a national public health conversation.Central to this story is Laura Ziskin, the Hollywood producer behind Pretty Woman and the Spider-Man films, whose metastatic breast cancer diagnosis inspired the creation of Stand Up To Cancer. Working alongside Couric and leaders from entertainment, journalism, and biomedical research, Ziskin championed a new funding model that required multidisciplinary scientific collaboration, helping accelerate discoveries that contributed to multiple FDA-approved cancer therapies. The episode also highlights the advocacy of actor Patrick Dempsey, whose family's experience with ovarian cancer led to the creation of the Dempsey Center, expanding support for patients and caregivers beyond medical treatment.The story also asks what celebrity advocacy often leaves unsaid. Financial toxicity, caregiver burden, chronic pain, mental health, and the long-term effects of treatment rarely receive the same attention as dramatic diagnoses or breakthrough cures. As cancer survivorship continues to evolve, the greatest challenge may not be convincing people to care about cancer, but helping them understand what it truly means to live with and beyond it.RELATED LINKSStand Up To CancerKatie Couric MediaDempsey CenterAmerican Association for Cancer ResearchNational Cancer InstituteDana-Farber Cancer Institute | Adult Survivorship ProgramFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In 2006, a landmark report titled Closing the Gap: Research and Care Imperatives for Adolescents and Young Adults with Cancer confirmed what young survivors had been saying for years. While survival rates for children and older adults had steadily improved, adolescents and young adults had experienced decades of stalled progress. They had become cancer's lost generation.This episode explores how young adult survivors transformed their shared isolation into one of the most influential grassroots movements in cancer advocacy. Diagnosed during the years typically devoted to education, careers, relationships, and starting families, patients between the ages of 15 and 39 confronted challenges that extended far beyond treatment. Fertility preservation, sexual health, employment, financial toxicity, insurance, and long-term quality of life were rarely discussed in oncology clinics, leaving many to navigate survivorship alone.The episode follows advocates including Tamika Felder, Lindsay Avner, Heidi Adams, Doug Ulman, and Dr. Archie Bleyer, whose research and advocacy fundamentally changed how medicine understands adolescent and young adult cancer. Through organizations including Planet Cancer, Fertile Hope, the Lance Armstrong Foundation, and later Stupid Cancer, survivors built online communities, educational resources, conferences, and national partnerships that challenged long-standing assumptions about cancer care. Their work helped establish fertility preservation as a standard discussion before treatment, expanded research dedicated to adolescent and young adult oncology, and elevated quality of life as a critical clinical outcome alongside survival.The movement also demonstrated the power of lived experience to reshape medicine. Survivors became researchers, educators, nonprofit founders, and policy advocates, insisting that cancer care account not only for years of life saved, but for the lives patients hoped to build afterward.What began as a search for peers evolved into a national movement that permanently transformed adolescent and young adult oncology. Today, dedicated research programs, clinical fellowships, survivorship resources, and patient advocacy organizations continue to build on the foundation these young cancer mavericks created.RELATED LINKSNational Cancer Institute | Adolescent and Young Adult (AYA) Cancer ProgramClosing the Gap: Research and Care Imperatives for Adolescents and Young Adults with CancerAmerican Society of Clinical Oncology | Fertility Preservation GuidelinesStupid CancerLivestrong FoundationJournal of Adolescent and Young Adult OncologyFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Nicole Locklin for US Congress is an attorney with more than a decade of legal experience, most recently serving as Lead Commercial Legal Counsel for Healthcare and Life Sciences at Databricks. She grew up in a town of about a thousand people in rural Oklahoma, where her parents ran a crop dusting business. A first generation college graduate who relied on student loans to earn her law degree, Nicole is now running as a Democrat for U.S. Congress in Florida's 26th District, challenging a twenty plus year incumbent and making the case that working families in South Florida deserve a representative who actually works for them.We talked about what it has actually felt like to leave a legal career and step into a congressional race with no political background, the affordability crisis Nicole keeps hearing about on doorsteps across South Florida where homeowner's insurance averages $8,000 a year and a one bedroom apartment can run nearly $3,000 a month, and why Nicole believes corruption and corporate money in politics is the root cause blocking progress on every other issue families care about. We also discussed the gerrymandering that reshaped FL-26, why Nicole sees the seat as genuinely flippable, and what it means to run a grassroots campaign in a state where the political establishment has spent years trying to erase Democratic votes.Connect with Nicole: Website | Instagram | Substack If you're looking to unleash your potential, find your personal, professional, or political fire, and to connect with a community who is doing the same, click here to learn more. This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit shannonwatts.substack.com/subscribe
Your thyroid may be small, but it plays a major role in your energy, metabolism, hormones, mood, and overall health. In this conversation, Dr. Michelle Robin and Bayleigh Soza sit down with Dr. Alicia Johnson to discuss common thyroid conditions, why symptoms can occur even when labs appear normal, and the importance of looking beyond surface-level answers. Together, they explore how stress, nutrition, blood sugar, hormones, vitamin D, and environmental factors can impact thyroid function. Dr. Johnson shares practical strategies for supporting thyroid health and explains how small, proactive steps can help prevent bigger health challenges in the future. Key Takeaways: Your thyroid influences every cell in your body, impacting energy, metabolism, mood, hormones, digestion, and overall health. Thyroid symptoms can occur even when standard thyroid lab results appear normal, making comprehensive testing important. Stress, blood sugar imbalances, environmental toxins, hormone fluctuations, and nutrient deficiencies can all affect thyroid function. Prevention matters—tracking health markers early can help identify issues before they become major health challenges. Simple lifestyle habits such as eating whole foods, maintaining healthy vitamin D levels, managing stress, and supporting key nutrients can improve thyroid and endocrine health. We couldn't highlight incredible stories like this without the support of our sponsor, CommunityAmerica Credit Union. Thank you for helping us promote connection, well-being, and stronger communities. If you're looking for trusted financial wellbeing resources, we invite you to connect with their team and take the next step toward greater financial confidence. About Dr. Alicia Johnson: Alicia Johnson is a licensed Doctor of Naturopathic Medicine. Her areas of expertise include medical weight loss, hormone balance, fatigue, anti-aging, and mood disorders. Dr. Johnson has a passion for getting to know her patients and working together as a team to address even the most complicated health concerns. Dr. Johnson utilizes natural, non-invasive therapies to treat many common conditions such as menstrual irregularities, menopausal symptoms, depression, anxiety, obesity, infertility, low testosterone, fatigue, digestive problems, and many other chronic conditions. Dr. Johnson is a graduate from Southwest College of Naturopathic Medicine in Tempe, AZ. She received her acupuncture training from the Phoenix Institute of Herbal Medicine and Acupuncture. Prior to medical school, she received her Bachelors of Science in Life Sciences with a secondary degree in Gerontology, the study of aging. Dr. Johnson's patients are treated individually with a combination of Bioidentical Hormone Replacement recommendations, acupuncture, nutritional supplementation, botanical medicine, dietary counseling, homeopathy, and lifestyle counseling. This unique, individualized approach is effective for improving the outcome of almost any chronic health condition because many chronic diseases simply do not respond well to simple pharmaceutical treatment. Connect with Dr. Alicia Johnson at: https://aspirehealthkc.com/ Connect with Dr. Michelle and Bayleigh at: https://smallchangesbigshifts.com hello@smallchangesbigshifts.com https://www.linkedin.com/company/smallchangesbigshifts https://www.facebook.com/SmallChangesBigShifts https://www.instagram.com/smallchangesbigshiftsco https://www.youtube.com/@smallchangesbigshiftsco Thanks for listening! Thanks so much for listening to our podcast! If you enjoyed this episode and think that others could benefit from listening, please share it using the social media buttons on this page. Do you have some feedback or questions about this episode? Leave a comment in the section below! Subscribe to the podcast If you would like to get automatic updates of new podcast episodes, you can subscribe to the podcast on Apple Podcasts or Stitcher. You can also subscribe in your favorite podcast app. Leave us an Apple Podcasts review Ratings and reviews from our listeners are extremely valuable to us and greatly appreciated. They help our podcast rank higher on Apple Podcasts, which exposes our show to more awesome listeners like you. If you have a minute, please leave an honest review on Apple Podcasts.
In 2006, the Institute of Medicine published From Cancer Patient to Cancer Survivor: Lost in Transition, concluding that millions of Americans were surviving cancer only to find themselves navigating a healthcare system unprepared for life after treatment. The report challenged oncology to recognize that curing cancer was not the end of care, but the beginning of survivorship.This episode explores how the growing cancer survivorship movement exposed the long-term consequences of cancer treatment that medicine had largely overlooked. As survival rates improved following the National Cancer Act of 1971, millions of survivors faced chronic fatigue, neuropathy, infertility, cognitive impairment, financial hardship, employment discrimination, anxiety, depression, and post-traumatic stress. These were not rare complications. They became defining features of survivorship for many patients.Drawing on the work of oncologist Dr. Patricia Ganz, survivor advocate Ellen Stovall, and researchers, clinicians, and survivors across the country, the episode examines how survivorship research expanded beyond recurrence and mortality to include quality of life, psychosocial care, rehabilitation, and long-term follow-up. Their efforts helped establish survivorship care plans, multidisciplinary survivorship clinics, and a broader understanding that cancer affects every aspect of a person's life long after treatment ends.The episode also confronts persistent inequities in survivorship care. Insurance coverage often ends when treatment stops, supportive services remain inconsistent, financial toxicity continues to drive medical hardship, and racial, geographic, and socioeconomic disparities still influence who receives comprehensive follow-up care. For many survivors, finishing treatment simply marks the beginning of another struggle.Modern oncology increasingly recognizes that surviving cancer is measured by more than years of life. It is also measured by quality of life, dignity, access to care, and the ability to rebuild a future after treatment. That evolution remains one of the most significant legacies of the cancer survivorship movement.RELATED LINKSNational Academy of Medicine | From Cancer Patient to Cancer Survivor: Lost in TransitionNational Cancer Institute Office of Cancer SurvivorshipAmerican Society of Clinical Oncology | Survivorship CompendiumCancerCareHopeWell Cancer SupportNational Coalition for Cancer SurvivorshipFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In 1967, breast surgeon Dr. Harold P. Freeman arrived at Harlem Hospital expecting to treat cancer. Instead, he confronted a healthcare system where poverty, racism, lack of insurance, and institutional barriers often determined who lived long enough to receive treatment. Patients frequently arrived with advanced disease, not because medicine lacked answers, but because access to care had failed them.This episode explores how cancer survivorship expanded beyond medical breakthroughs to include healthcare access, health equity, and organized advocacy. Building on the early work of the National Coalition for Cancer Survivorship (NCCS), it examines the recognition that surviving cancer depended not only on research, but also on whether patients could navigate a fragmented healthcare system.Freeman responded by creating one of the nation's first patient navigation programs at Harlem Hospital in 1990. Community-based navigators helped patients overcome practical barriers including insurance, transportation, appointments, communication, and fear. The model dramatically improved timely diagnosis and treatment, increased breast cancer survival in Harlem, and ultimately inspired the Patient Navigator Outreach and Chronic Disease Prevention Act of 2005, establishing navigation as a cornerstone of modern oncology care.The episode also follows cancer survivor Ellen Stovall, whose leadership transformed survivorship into a national policy movement. Through the NCCS, she united advocates across cancer types, fought for insurance protections, expanded access to clinical trials, helped shape the creation of the Office of Cancer Survivorship at the National Cancer Institute, and organized the landmark 1998 National March for Cancer Survivorship in Washington, D.C. Her work reframed survivorship as a public policy issue rather than a personal experience.Together, Freeman and Stovall demonstrated that scientific progress alone could not eliminate disparities in cancer outcomes. Their work established two enduring principles that continue to shape oncology today: patients need someone to help them navigate care, and survivors must have a voice in the policies that govern it. Modern cancer survivorship depends on both.RELATED LINKSNational Coalition for Cancer SurvivorshipHarold P. Freeman Patient Navigation InstituteNational Cancer Institute Office of Cancer SurvivorshipPatient Navigator Outreach and Chronic Disease Prevention Act of 2005American Cancer SocietyTuskegee Study Timeline | Centers for Disease Control and PreventionFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Welcome to a very, very, very special bonus episode of Out of Patients, and one unlike anything published on this feed before. For nearly 20 years, Matthew Zachary has handed these microphones to patients, caregivers, doctors, advocates, troublemakers, and people with something worth saying. This time, he handed them to his daughter. Hannah Greenzweig grew up around this show, and now she has commandeered the studio with 3 of her wonderfully creative high school friends to talk about something they built entirely themselves. There is an enormous amount of Dad Pride baked into this episode, along with the strange and wonderful realization that sometimes your kid grows up, takes your chair, takes your microphone, and produces a better show without you.Hannah Greenzweig, Michael Aidinov, Gwendolyn Baldini, and Astronomy are student artists from the Roundabout Youth Ensemble at James Madison High School in Brooklyn. Working alongside teaching artists from Roundabout Theatre Company, they spent a school year creating an original play from the ground up, writing every scene, developing every character, and producing the performance themselves.Instead of discussing a Broadway production, they dissect one they invented.Their play, Subject Matter, began with a room full of improbable ideas. Murderous bounce houses, pirate family sagas, underwater adventures, courtroom dance battles, and birthday parties at math museums all competed before the group settled on an absurd rivalry between New York's fictional History Museum and Math Museum. From there, they built a fully staged comedy about institutional competition, sabotage, oversized personalities, and the unexpected discovery that history and mathematics need each other more than either side wants to admit.The conversation pulls back the curtain on a creative process most audiences never see. The students explain how scenes evolved through constant rewrites, how characters emerged from improvisation, how costumes came together with last minute ingenuity, and how rehearsals often collapsed into uncontrollable laughter. They recount cutting favorite ideas, solving production problems with limited resources, and trusting each other enough to keep rewriting until the story worked.The episode also captures something harder to script: teenagers speaking honestly about collaboration without adults translating their experience. They celebrate classmates who stepped into unexpected roles, teachers who quietly held the production together, and the strange joy of creating something that exists only because everyone showed up.It is a conversation about theater, friendship, education, creativity, and what happens when 4 young artists get the microphones and the adults get out of the way.RELATED LINKSRoundabout Theatre CompanyRoundabout Youth EnsembleJames Madison High SchoolFEEDBACKLike this bonus episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
A man is struck by a car on the streets of Los Angeles. In the emergency department, a CT scan ordered to look for traumatic injuries reveals something nobody expected: a mass in his colon. Days later, sitting across from Dr. Belinda Waltman, he calls the accident “a blessing in disguise.” Then he changes the subject. He is less worried about cancer than about whether he can afford to miss another day of work. In this season finale of Standard Deviation, host Dr. Oliver Bogler explores what happens when biomedical science collides with the realities of the healthcare safety net. Dr. Waltman, a primary care physician in Los Angeles County, specializes in expedited cancer workups for uninsured and underinsured patients. Every diagnosis arrives carrying another set of questions about housing, transportation, food insecurity, wages, and survival that rarely appear in medical records or scientific literature. For years, Waltman carried those stories without knowing how to bring them into the academic record. As a full-time clinician without a research lab, grant funding, or publication pipeline, she faced barriers familiar to many working scientists and physicians whose most important observations happen outside traditional research settings. With support from the Life Science Editors Foundation's JEDI program, those experiences became The Margins Matter, a narrative medicine essay published in JAMA that argues the social realities surrounding cancer care are not background details. They are part of the disease itself. Bogler traces how editorial mentorship transformed lived clinical experience into published scholarship while asking a larger question about who gets to shape the scientific record. The conversation examines cancer care, Medicaid, health-related social needs, medical publishing, and the structural incentives that determine which stories become evidence and which disappear from view.The result is a conversation about documentation, visibility, and why the margins of medicine often determine who survives long enough to benefit from its advances.RELATED LINKSDr. Belinda WaltmanThe Margins Matter | JAMAThe Margins Matter | PubMedLife Science Editors FoundationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode of Tiny Show and Tell Us, we explore how scientists are using evolutionary methods to reconstruct the history of folktales like Little Red Riding Hood, Beauty and the Beast, and Jack and the Beanstalk. Then guest Matt Gabriele, professor of medieval studies and host of the podcast American Medieval, shares his fascination with Greenland sharks, leading us into the science of radiocarbon dating, longevity genetics, and the ongoing debate over whether these elusive deep-sea predators truly live for 400 years or more.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org or fill out this form with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
GLPs are everywhere right now — but do you actually know what they are or what they do? In this episode I break down the reality of GLP-1, what it is, how it works, and how your body already has the natural ability to activate it through a fasting-focused lifestyle. Whether you're considering the shot or just curious about how it all works, this episode gives you the full picture so you can make the best decision for your health and future. _____ Are you ready for real, compassionate support on your fasting journey from someone who has actually lived it? I've shed over 200 pounds through fasting and have maintained it through some of the hardest seasons of life. If you're tired of doing this alone, you don't have to anymore. Come find your people: The Fasting Support Club _____ REFERENCES Habener, J.F. (2004). The discovery of glucagon-like peptide 1. ScienceDirect — Molecular and Cellular Endocrinology. Retrieved from sciencedirect.com Mass General Brigham Newsroom. (2025). Joel Habener receives Breakthrough Prize in Life Sciences for contributions to GLP-1 medications. Retrieved from massgeneralbrigham.org Journal of Clinical Investigation. (2024). Joel Habener, Svetlana Mojsov, and Lotte Bjerre Knudsen awarded Lasker Prize for pioneering work on GLP-1. Retrieved from jci.org Eng, J. (1992). Discovery of exendin-4 in Gila monster venom. VA Medical Center, Bronx, NY. Referenced in: PlexusDx. (2026). History of GLP-1 drugs: Complete timeline from exenatide to tirzepatide. Retrieved from plexusdx.com Fella Health. (2025). What is GLP-1 lizard venom: Gila monster discovery to diabetes drugs. Retrieved from fellahealth.com U.S. Food and Drug Administration. (2005). Approval of exenatide (Byetta) for type 2 diabetes. FDA Drug Approval Database. Acosta, A. & Ghusn, W. (2023). Semaglutide shown to be effective for weight loss in multicentre, one-year real-world study. European Congress on Obesity (ECO2023). Presented by Precision Medicine for Obesity Program, Mayo Clinic. Retrieved from eurekalert.org Mayo Clinic Press. (2026). Health benefits of semaglutide beyond weight loss. Retrieved from mcpress.mayoclinic.org National Institutes of Health / NCBI. (2024). Patient perceptions of Ozempic (semaglutide) for weight loss: Mixed methods analysis of online medication reviews. Retrieved from ncbi.nlm.nih.gov National Institutes of Health / NCBI. (2024). Evaluation of pre-treatment assessment of semaglutide users: Balancing the benefits of weight loss vs. potential health consequences. Retrieved from ncbi.nlm.nih.gov Fung, J. (2016). The Obesity Code: Unlocking the secrets of weight loss. Greystone Books. Fung, J. (2025). The Hunger Code: Resetting your body's fat thermostat in the age of ultra-processed food. Greystone Books.
Idaho's Palouse Region is off the beaten path for many, but it's where a significant impact is made to help keep farmers productive and consumers well-fed. With a storied history dating back to the 19th century, the University is Idaho is one of the nation's premier public research institutions. Redox was provided a campus tour, including the Soil Stewards Farm and Deep Soil Ecotron."Collectively together we have the opportunity to really lean in and make sure that we're providing as your land grant university the research that's needed to help our producers be successful," remarked Leslie Edgar, J.R. Simplot Endowed Dean of the University of Idaho's College of Agricultural and Life Sciences. Find out more about the University of Idaho and how it helps farm productivity at uidaho.edu/cals.
In 1986, 23 survivors, physicians, nurses, attorneys, and community organizers gathered in Albuquerque, New Mexico, for a weekend that would permanently change the language and politics of cancer. Working late into the night, they debated not only strategy, but identity, ultimately declaring that from the moment of diagnosis, every person with cancer is a survivor.This episode traces the social and political forces that gave birth to the modern cancer survivorship movement. As advances in early detection and treatment allowed more people to live beyond cancer, survivors discovered that finishing treatment did not mean returning to normal life. Many faced employment discrimination, loss of insurance, social stigma, infertility, chronic health complications, and a healthcare system that viewed survival as the end of care rather than the beginning of a new chapter.Against the backdrop of the civil rights, disability rights, and community health movements of the 1960s and 1970s, physicians, activists, and survivors challenged medicine's paternalistic culture and demanded a greater voice in decisions affecting their lives. Central to this story are physician and survivor Dr. Fitzhugh Mullan, whose landmark 1985 essay, Seasons of Survival, redefined survivorship as a lifelong continuum, and community organizer Katherine Logan, whose determination united dozens of grassroots organizations into what became the National Coalition for Cancer Survivorship.The coalition's founding established principles that continue to shape oncology today. Survivors were no longer defined solely by disease or treatment outcomes. Their experiences became evidence. Their voices became essential to clinical research, healthcare policy, and patient advocacy. By redefining survivorship as an ongoing experience rather than a destination, the movement challenged medicine to recognize the lasting physical, emotional, financial, and social consequences of cancer.The ideas forged during that weekend in Albuquerque became the foundation of modern cancer survivorship. Nearly 40 years later, the coalition's defining principle, that survivorship begins at diagnosis, continues to influence cancer care, research, policy, and the way millions of people understand life after cancer.RELATED LINKSNational Coalition for Cancer SurvivorshipNational Cancer Institute Office of Cancer SurvivorshipThe New England Journal of MedicineAmericans with Disabilities Act (ADA.gov)Library of Congress | Civil Rights History ProjectWhite Coat, Clenched Fist by Fitzhugh MullanFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Episode 82 - Matthew Whitty, former NHS England Director of Innovation, Research and Life Sciences and now Director of Commercial Partnerships at MDClone, discusses NHS data strategy, safe AI adoption and protecting patient privacy.Disclaimer: Please note that all information and content on the UK Health Radio Network, all its radio broadcasts and podcasts are provided by the authors, producers, presenters and companies themselves and is only intended as additional information to your general knowledge. As a service to our listeners/readers our programs/content are for general information and entertainment only. The UK Health Radio Network does not recommend, endorse, or object to the views, products or topics expressed or discussed by show hosts or their guests, authors and interviewees. We suggest you always consult with your own professional – personal, medical, financial or legal advisor. So please do not delay or disregard any professional – personal, medical, financial or legal advice received due to something you have heard or read on the UK Health Radio Network.
In dieser Episode des Deloitte Future Talk sprechen wir über ein Phänomen, das oft missverstanden wird: regionale wirtschaftliche Unterschiede. Sind sie ein Problem, oder die Lösung? David Marmet, Chefökonom Schweiz der Zürcher Kantonalbank, erklärt, warum Kantone und Bundesländer konkurrieren sollten und wie dieser regionale Wettbewerb Innovation und Wohlstand schafft. Die unbequeme Wahrheit über regionale Unterschiede Zwischen dem Kanton Zürich und dem Tessin gibt es Lohnunterschiede von etwa 30 Prozent, ähnlich auch bei deutschen Bundesländern. Das ist erheblich. Und doch ist das Tessin nicht weniger produktiv als Zürich. Wie kann das sein? David Marmet zeigt, dass regionale Unterschiede nicht das Problem sind, sondern ein Zeichen von funktionierendem Wettbewerb. Warum Spezialisierung und Cluster entscheidend sind Nicht alle Regionen sind gleich. Basel konzentriert sich auf Life Sciences, Zürich auf Finanzdienstleistungen und Tech, das Tessin auf Kultur und Kreativität. Doch was passiert, wenn eine Region zu sehr auf ein Pferd setzt? Und welche Risiken birgt extreme Spezialisierung? Weitere Fragen dieser Episode: Warum hat Zürich die höchsten Löhne, aber das niedrigste Produktivitätswachstum? Wie erklärt sich die «Baumolsche Krankheit» und warum macht sie Dienstleistungsregionen stabiler? Kann Föderalismus und Wettbewerb Ungleichgewichte zwischen Regionen ausgleichen? Was sind die Rezepte für hohe regionale Wettbewerbsfähigkeit – und was können Kantone und Bundesländer voneinander lernen? Ein spannendes Gespräch über unsichtbaren Marktkräfte, die Regionen prägen, und warum Unterschiede nicht das Problem sind, sondern die Chance. LinkedIn Profil David Marmet Studienreihe "Zürcher Wirtschaft im Fokus": https://www.zkb.ch/de/private/anlagen/rechner-hilfsmittel.html Kanton Zürich / Deloitte Studie: Rezepte gegen den demografisch bedingten Wohlstandsverlust Neben Apple Podcast kannst du unseren Podcast auch bei Spotify, SoundCloud, Google und anderen Podcast Apps hören. Über Dein Feedback und Deine Anregungen zu dieser Episode freuen wir uns sehr. Besuche uns auf unseren Websites Deloitte Schweiz und Deloitte Deutschland Oder schreibe uns auf LinkedIn: LinkedIn Alexander Börsch LinkedIn Michael Grampp
S1E7: Caris Life Sciences Series - Part 1 of 3: The Science: Advancements in molecular profiling (WES + WTS) and impact on cancer care Host Shahid Shah with his guest James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance™ (Caris POA). To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen
Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.
In 1971, President Richard Nixon signed the National Cancer Act, transforming cancer research with an unprecedented federal investment and launching what became known as the War on Cancer. The legislation did not emerge from scientific discovery alone. It was the culmination of decades of relentless advocacy by researchers, philanthropists, journalists, and patients who believed cancer demanded the same national commitment that had put astronauts on the Moon.This episode traces the origins of the cancer survivorship movement by returning to a time when cancer was rarely discussed in public, many physicians withheld diagnoses from their patients, and surgery offered few lasting cures. It follows the pioneering work of pathologist Dr. Sidney Farber, whose early chemotherapy research challenged conventional thinking, and Mary Lasker, whose political strategy, fundraising, and public campaigns helped transform cancer from a private tragedy into a national public health priority. Together, they built the coalition that reshaped federal support for oncology research and forever changed the relationship between science, government, and the American public.The story then turns to journalist and breast cancer survivor Rose Kushner, whose refusal to accept the standard one-step radical mastectomy challenged nearly a century of surgical dogma. Working alongside surgeon Dr. Bernard Fisher, Kushner helped bring evidence-based medicine to breast cancer treatment through randomized clinical trials that demonstrated less invasive surgery could achieve equivalent outcomes. Their efforts changed clinical practice, strengthened informed consent, and helped establish the principle that patients should participate in decisions about their own care.The breakthroughs explored in this episode extended far beyond new treatments. They redefined the role of patients in medicine, accelerated clinical research, and laid the foundation for modern cancer survivorship. The movement that followed would not simply help more people live longer. It would change what surviving cancer meant.RELATED LINKSNational Cancer InstituteNational Cancer Act of 1971American Cancer SocietyDana-Farber Cancer InstituteNational Library of MedicineThe New England Journal of MedicineFEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Please send any questions to podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Biotech Bytes: Conversations with Biotechnology / Pharmaceutical IT Leaders
Empathetic AI and the Future of Work in Life Sciences #aiinlifesciences #pharmaai #biotechbytesArtificial intelligence is shifting how biotech and pharmaceutical teams operate in the field. Rather than replacing sales reps or medical science liaisons, the real power of technology comes from making employees better at what they do. In this episode of Biotech Bytes, host Steve Swan speaks with Parth Khanna, CEO and Co-founder of ACTO, about using empathetic AI to support a bionic employee workforce. Please visit our website to get more information: https://swangroup.net/ Parth explains how intelligent field excellence platforms give customer-facing teams quick access to clinical data, personalized training, and real-time coaching. They discuss why human connection, trust, and strict compliance matter when introducing AI agents into healthcare.Key topics covered in this video:• Why AI should augment human skills instead of replacing workers• How field reps and medical science liaisons use AI agents to prepare for calls and learn faster• The role of compliance, governance, and trust in enterprise AI adoption• How human judgment and AI support work together to shape the future of workLinks from this episode:✅ Get to know more about Steven Swan: https://www.linkedin.com/in/swangroup ✅ Get to know more about Parth Khanna: https://www.linkedin.com/in/parthkhanna ✅ Learn more about Acto: https://acto.com
Before modern blood transfusions, doctors tried some odd alternatives, including cow's milk. In this episode, we trace the fascinating history of blood transfusions, from risky animal experiments and failed milk injections to the discovery of blood types and disease screening. You'll hear how blood transfusions became one of medicine's safest procedures, why researchers are still debating exactly when patients need them, and what innovations could make blood easier to store, transport, and use in emergency situations including the military battlefield.Check out Dreaming Against the Machine here or wherever you listen to podcasts!A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
How can marketing teams in the life science vertical show up stronger online and drive higher organic visibility for their organizations? Operating in a heavily-regulated industry where market competition is intense, many life science marketing teams stay quite busy, yet their pipelines are quiet, hampering long-term business growth? How can life science leaders bridge this gap and turn things around?That's why we're talking to Lauren Schafer (Founder, Lake House Digital Media), who shares proven ways to build life sciences buyer trust for predictable growth. In this episode, Lauren discussed the high-impact strategies for building deep authority and trust in the life science industry. She highlighted the value of uncovering specific client pain points and tailoring marketing approaches without being too generic. Lauren also stressed the significance of LinkedIn for B2B marketing, noting that decision-makers often conduct independent vendor research on the platform. She advised maintaining an up-to-date profile, using background banners effectively, and how you can be active and responsive on the platform. Lauren also emphasized the value of providing transparent marketing analytics dashboards to demonstrate accountability and ROI, essential for leadership buy-in.
Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer SocietyNational Cancer InstituteAmerican Film InstituteER (NBC)50/50 (Official)Chasing Life (ABC Family Archive)FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Digital, real, real, digital. It sounds simple, but it's rewriting how a warehouse gets designed.Joel Thomas has spent over a decade in the Intralogistics space and now leads OEM Sales Data Center and Life Sciences at Siemens. Markus Thiel just crossed the six month mark as Head of Intralogistics, after years on the manufacturing operations and supply chain side of the business.Chris caught up with both of them live in Atlanta during MODEX, over a Weiss beer and a pilsner at Halfway Crooks. They talk about what Intralogistics is, and how it's changed since the days of pallet jacks and conveyor belts.From there the conversation covers the industry engineer shortage, robotics, AGVs versus AMRs, why standardization is becoming such a hot topic among vendors, and what a warehouse looks like when it's designed digitally.In this episode, find out:How the day-to-day work of moving goods within a warehouse has changed over the past decadeThe shift to robotics, AGVs, and AMRs, and why orchestrating all of it is now the hard partWhy standardization is gaining ground even though flexibility with vendors used to be the priorityHow AI is being used to spot bottlenecks and predict maintenanceWhat edge computing means for a warehouseWhat it takes to build a digital twin, and why Siemens tests new technology in its own factory firstWhether a conveyor-less warehouse is realistic, and who's already exploring itWhy e-commerce has been the single biggest driver of growth in the industryWhat's next for the space, software-defined automation and the IT/OT layerEnjoying the show? Please leave us a review here. Even one sentence helps. It's feedback from Manufacturing All-Stars like you that keeps us going!Tweetable Quotes:"We want more individualized goods, and we want it faster and sooner, so that thing will not stop. It will further accelerate. It's great to see all the technology which is helping that development.” - Markus Thiel, Head of Intralogistics at Siemens“It was always about taking off your professional hat, and just being a person. Go out and talk to people and just introduce yourself. The one great thing that you can do in this industry is say, ‘Can I help?'” - Joel Thomas, Director of OEM Sales Data Center and Life Sciences at Siemens”If you asked me 7 years ago, I would say that Europe was way ahead when it came to automation technology. Now, I think the US has caught up, if not maybe surpassed it.” - Joel Thomas, Director of OEM Sales Data Center and Life Sciences at SiemensLinks & mentions:Siemens Intralogistics provides intelligent material handling tech that empowers intralogistics to meet demands and overcome challenges via AI-enhanced automation and sustainable design.MHI the nation's largest material handling, logistics and supply chain association - active since 1945.Halfway Crooks Beer is the Atlanta brewery where this episode was recorded, known for traditionally brewed lagers in the Summerhill neighborhood.Make sure to visit http://manufacturinghappyhour.com for detailed show notes and a full list of resources mentioned in this episode. Stay Innovative, Stay Thirsty.
Matthew Whitty is the former Director of Innovation, Research and Life Sciences at NHS England and now Director of Commercial Partnerships at MDClone, a global healthcare data platform. Combining senior NHS leadership with frontline experience in healthcare data and AI, he is an expert on NHS data strategy, safe AI adoption and how health systems can unlock the value of data while protecting patiWho actually owns your health data? Most people assume there's a single patient record sitting somewhere in the NHS. There isn't, and that gap sits at the heart of one of healthcare's most important and least understood debates.This week, Steve Roest is joined by Matthew Whitty, Director of Commercial Partnerships at MDClone and former Director of Innovation, Research and Life Sciences at NHS England. Drawing on a career that's spanned hospital pharmacy, commissioning, consultancy and national policy, Matt offers a rare view from the intersection of government, industry, academia and patient care.Together they unpack why the "privatisation" debate is really about trust and motivation, what the Federated Data Platform and the Palantir contract actually involve, and why de-identified data can still put patients at risk - including the recent UK Biobank breach. They also explore synthetic data, the case for sandbox environments that could make Britain the number one place to build healthtech, and why Matt believes there's far more reason for optimism about the NHS than the headlines suggest.In this episode:Why the NHS can't build everything itself, and what the private-sector "tension" is really aboutWho owns your health data, and why no single patient record existsThe Federated Data Platform and Palantir controversy, explainedHow de-identified data gets re-identified, and what happened with UK BiobankSynthetic data and the case for UK healthtech "sandboxes"Why the NHS may compare far better to other systems than people assume
Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.
Debi Evans shares her journey into alternative media and describes how the 2020 health crisis served as a data harvesting exercise and “warm-up act” for a broader globalist agenda. The discussion examines the UK's role as a laboratory for life sciences, where the population is subjected to experimental medical treatments and surveillance. These agendas (e.g. Absolute Zero, Agenda 2030) are designed to restrict human movement and enforce algorithmic tyranny. Furthermore, Debi explores the rise of transhumanism, warning that the integration of AI into daily life may lead to the eventual extinction of human autonomy. Ultimately, the conversation portrays a dystopian future where manufactured crises in health, energy, and water are used to usher in a new world order. Watch on BitChute / Brighteon / Rumble / Substack / YouTube *Support Geopolitics & Empire! Become a Member https://geopoliticsandempire.substack.com Donate https://geopoliticsandempire.com/donations Consult https://geopoliticsandempire.com/consultation **Listen Ad-Free for $4.99 a Month or $49.99 a Year! Apple Subscriptions https://podcasts.apple.com/us/podcast/geopolitics-empire/id1003465597 Supercast https://geopoliticsandempire.supercast.com ***Visit Our Affiliates & Sponsors! Above Phone https://abovephone.com/?above=geopolitics American Gold Exchange https://www.amergold.com/geopolitics Escape The Technocracy (15% off w/ GEOPOLITICS!) https://escapethetechnocracy.com/geopolitics Expat Money (FREE “WW3 Plan-B” Report!) https://expatmoney.com/geopolitics PassVult https://passvult.com Sociatates Civis https://societates-civis.com StartMail https://www.startmail.com/partner/?ref=ngu4nzr Wise Wolf Gold https://www.wolfpack.gold/?ref=geopolitics Websites X https://x.com/DebiEvansMatron Camp 3 News https://www.camp3news.com About Debi Evans Debi Evans is a retired NHS SRN and contributor to Camp 3 News among other independent media. *Podcast intro music used with permission is from the song “The Queens Jig” by the fantastic “Musicke & Mirth” from their album “Music for Two Lyra Viols”: http://musicke-mirth.de/en/recordings.html (available on iTunes or Amazon)
Healthcare affordability continues to be one of the defining challenges facing the industry. In this episode of PwC's Next in Health, Glenn Hunzinger is joined by Thom Bales, Derek Skoog, and Philip Sclafani to discuss the findings from PwC's Behind the Numbers 2027 report and the forces driving medical cost trends toward 9% in 2027. From AI-enabled documentation and provider reimbursement to GLP-1 therapies, behavioral health, and payment integrity, the conversation explores what's contributing to rising costs—and where healthcare leaders can focus to improve affordability while continuing to advance innovation and patient care. Discussion highlights:Medical cost trends approaching 9% and the forces driving healthcare inflationAI's growing influence on clinical documentation, payment integrity, and reimbursementInnovation's impact on affordability, from GLP-1 therapies to cell and gene therapiesStrategies health plans, employers, and providers are using to improve affordability and reduce frictionThe evolving role of reimbursement, utilization management, and payment integrity in managing costsWhat rising medical costs mean for employers, consumers, and the future of healthcareSpeakers:Glenn Hunzinger, US Health Industries Leader, PwCThom Bales, US Health Services Advisory Leader, PwCDerek Skoog, Principal, Health Services, PwCPhilip Sclafani, Principal, Pharmaceutical and Life Sciences, PwCFor additional insights, check out our Behind the numbers 2027 report at https://www.pwc.com/us/en/industries/health-industries/library/behind-the-numbers.htmlFor more information, please visit us at: https://www.pwc.com/us/en/industries/health-industries/health-research-institute/next-in-health-podcast.html.
AI is moving fast — but is life science actually adopting it?In this episode of Discovery Matters, we explore how artificial intelligence is being used across pharma and life sciences, and where progress is still cautious. Joined by Joe Luminiello, CEO of RCG Intel, we discuss the balance between speed and safety, innovation and regulation, and why human context still matters as much as algorithms.Cutting through the hype, this conversation asks not just whether the industry should use AI — but how to do it thoughtfully.
In this episode of Tiny Show and Tell Us, we dive into the surprisingly elaborate world of occlupanids: the humble plastic bread bag clips that have inspired an entire taxonomy complete with Latin names, species classifications, and a community of collectors. Then, we investigate a strange power outage in central Texas, where power poles caught fire after a light drizzle. We unpack the science behind pole-top fires, the "Goldilocks" weather conditions that fuel them, and the surprising technologies being used to inspect and maintain power grids across the world. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
This New Statesman podcast episode has been fully funded by argenx and features an edited panel discussion recorded at the New Statesman's Igniting Growth Conference.The UK has world-leading science, research and regulatory expertise, but too often struggles to turn those strengths into investment, innovation and better patient access.Can it turn its life sciences strengths into global leadership?Chaired by New Statesman policy correspondent Samir Jeraj, the panel brings together Dame Chi Onwurah MP, Naomi Weir from the CBI, David Knechtel from argenx UK and Ireland, and Clare Pelham from the Epilepsy Society.Our panel discusses why the UK's scientific and regulatory strengths are not consistently translating into growth and patient access, as well as the commercial pressures affecting confidence in the sector.They talk about the need for more joined-up delivery across government, the NHS and industry, how innovation can reach patients, and what must change for the Life Sciences Sector Plan to deliver.LISTEN AD-FREE:
Most health systems aren't asking whether to modernize patient monitoring; they're asking whether the upgrade in front of them is worth it. In this episode, two Intel Healthcare and Life Sciences engineers make the case that the real decision isn't about simply adding AI to a monitor; it's about whether your monitoring infrastructure is built for an AI-native, distributed care model — or whether it's locking you into a siloed architecture that limits your options as care delivery evolves.
Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
AI is moving fast in life sciences, but a confident answer is not the same thing as a correct, reproducible, auditable answer. Knowledge graphs, ontologies, and FAIR data practices are the keys to bridging this gap. Knowledge3's Tom Plasterer, CEO and co-founder, and Eric Little, chief data officer, join host Allison Proffitt to discuss what it takes to turn semantics into something practical: a knowledge product mindset, modular delivery, and “semantic ops” that can better manage data systems. Their conversation challenges the hype cycle around context graphs, explains why life sciences are a natural starting point for regulated, high-stakes AI, and shows how layered models can capture the right level of context without building a giant monolith that never takes off. Links from this episode: Bio-IT World BioTeam Bio-IT World Europe Knowledge3 Bio-IT World's Trends from the Trenches podcast delivers your insider's look at the science, technology, and executive trends driving the life sciences through conversations with industry leaders.
Three Wisconsin counties have been the first to detect tar spot in corn fields. Pam Jahnke gets the latest update from Dr. Damon Smith, UW-Extension Plant Pathologist. Smith says the plant symptoms we're seeing today started with injury and infection weeks ago. Smith says the current hot and dry weather in Wisconsin has successfully lowered the risk of major crop diseases, providing a "saving grace" after a wet, mild June that initially raised concerns about disease potential. Current infections resulted from favorable conditions three to four weeks ago. Smith says disease pressure will likely increase if rainfall returns, creating a "race" to mature the corn crop before the disease compromises it. He says advancements in hybrid genetics are providing "partial resistance," which helps by creating smaller spots and slowing down secondary infection cycles, allowing the crop more time to reach maturity. Smith is also keeping an eye on the potential for white mold in Wisconsin soybeans. He says, again, the risk for white mold has dropped significantly due to the hot, dry weather. He does not though that irrigated fields continue to face a different risk profile and should still be monitored carefully. We get a break from some of the heat today according to Stu Muck. That will give folks in the Fox Valley a chance to clean up after a tornado rumbled through Menasha. Rainfall reporters said they received anywhere from 1.5" of rain to literally nothing in the whirlwind weather activity that crossed the state. Did you ever wonder if that farm equipment you bought a decade ago is worth what you paid? Ashly Huhn from the Steffest Group did a little research. He looked at 3 pieces of popular farm equipment and found out that the equipment's maintenance matters. Huhn says if equipment has been maintained and cared for, many sellers recoup almost 80% of their investment in some cases. Paid for by Steffes Group. Troy Runge has assumed a new leadership role on the UW-Madison campus as the interim dean of the College of Agriculture and Life Sciences. Dean and Director Glenda Gillaspy announced that she will move into a new role serving as the university’s director of the Wisconsin Rural Partnerships Institute. Hello Mexican cattle! USDA has announced it will allow Mexican cattle back into the United States despite ongoing concerns over New World Screwworm. John Heinberg, market advisor with Total Farm Marketing in West Bend says this sent the cattle market into a tailspin. He notes that this sell off has been building. He also says rain that moved across Nebraska overnight has taken a lot of the weather premium out of the grain trade.See omnystudio.com/listener for privacy information.
Welcome to the Podcast of Southwest Bible Fellowship in Tempe, Arizona. WHO ARE WE? • We are a group of people who are committed to living the grace life as set forth by the apostle of the Gentiles, the Apostle Paul. • We come together to study our Bibles, and yes, we believe we have God's perfect Word in the King James Bible. It and it alone is our final authority in all matters of faith and practice! • We do not come together and study our Bibles for the intent of being smarter than others. We understand that knowledge for the sake of knowledge is purely vain and serves no Godly purpose. • We do come together and study our Bibles for the intent of knowing our Lord Jesus Christ and the power of His resurrection. (Philippians 3:10) • We do come together and study our Bibles to understand that we have been crucified with Christ; nevertheless we live; yet not us, but Christ liveth in us: and the life which we now live in the flesh, we live by the faith of the Son of God, who loved us and gave himself for us. (Galatians 2:20) • We do come together and study our Bibles to understand that because Jesus Christ shed His blood for us and we should not live for ourselves but for Him, who died for us and rose again. (2 Cor. 5:15) • We do not claim to have attained to these lofty goals, but we press toward the mark of the prize of the high calling of God in Christ Jesus. (Philippians 3:14) You can donate to this ministry through www.butnow.org and the PayPal button on the homepage.
This week on "The Top Line," Fierce Healthcare and Life Sciences' editor-in-chief steps behind the microphone for a solo episode highlighting several of the biggest stories in biopharma. The episode covers GSK’s first lung cancer approval following its acquisition of Nuvalent, Axiom Biosciences’ unusual plan to list first in Hong Kong before pursuing a Nasdaq co-listing amid a resurgent biotech IPO market, and the U.S. House’s passage of legislation directing the FDA to update its animal testing rules. The episode also includes an update from the Fierce newsroom, including the arrival of a new Fierce Biotech staff writer, and a reflection on why human judgment, curiosity and original reporting matter more than ever. To learn more about the topics in this episode: GSK secures first lung cancer approval as FDA clears Jideytro in quick payoff from Nuvalent deal ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong Kong House passes bill directing FDA to update animal testing rules See omnystudio.com/listener for privacy information.
A sugar pill shouldn't work as well as a real drug ... except sometimes it does. In this episode, we explore the fascinating science of the placebo effect and how expectations can shape biological outcomes. From open-label placebos and AI healthcare chatbots to the nocebo effect, we unpack what scientists know, what they still don't understand, and why the placebo response is still largely mysterious. Check out Spirits here or wherever you listen to podcasts!A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
“The future of biology is programmable.”To give you a sense of how important this topic is, Patrick Hsu is the first guest we've had back to Ground Truths since the podcast began a few years ago. Nearly 2 years ago we spoke about digital biology but so much has happened since to help unravel the complexities in the language of life. Patrick is a co-founder and core investigator at the Arc Institute. His work is at the intersection of biology, engineering, and AI. At the ripe old age of 33, he's a pioneer of genome editing technologies and my go-to for tracking progress in digital biology. Besides that he's a great explainer with frequent use of metaphors and simplification of very complicated stuff.Here's what we discussed with the relevant links:—Our recent review in Nature Biotechnology on the large language of life models (LLLMs). GBAI-generalist biological artificial intelligence —The 2 multi-agent AI Nature papers in May for accelerating drug discovery: Full House (Robin) and Google Deep Mind (Co-Scientist) Multiple drug candidates were described as an outgrowth of multi-agent AI , with a 200-fold decrease in workflow time.Below Figure from synthesis of the Robin and Co-Scientist papers: “AI devises hypotheses and ways to test them,” Nature News and Views, by Oliver Elemento—Biomni published in Science 9 JulyAn infographic by NotebookLM below helps give you a sense of what—a diversity of important tasks— accomplished by Biomni—New workbench offerings by the AI companies including Anthropic's Claude Science, Open AI, Google DeepMind and the competition with academic spinoffs—Spud Cells —Virtual Cell project, which it's such a big deal, and the importance of perturbations—Alzheimer's disease with OpenAI for finding mechanistic new targets for drug discovery—The Nature Editorial —Mid-Journey's Ultrasound Imaging of the “Whole-Body” (and we're not imaginative enough, the need to think big)—Mitigating the worries about humans as lab assistants and nefarious use to produce bioweapons *******************************************************************************A big thanks to Ground Truths subscribers from every US state and 212 countries. Your subscription to these free essays and podcasts makes my work in putting them together worthwhile. If you're not a subscriber, please join!If you found this interesting PLEASE share it!Paid subscriptions are voluntary and all proceeds from them go to support Scripps Research. They do allow for posting comments and questions, which I do my best to respond to. Please don't hesitate to post comments and give me feedback. Let me know topics that you would like to see covered.Many thanks to those who have contributed—they have greatly helped fund our summer internship programs for the past two years. It enabled us to accept and support a record number of 61 summer interns here with us now! These are high school, college and medical students selected from thousands of applicants. We couldn't do this expanded program without the funds coming in through Ground Truths.Finally, thank you Alan Heldman MD, Bob Fleischman, Jeanie, Maureen Susannah, Mary Powers, and more than 400 others for tuning into my live video with Patrick Hsu! Join me for my next live video in the app. Get full access to Ground Truths at erictopol.substack.com/subscribe
As pharmaceutical manufacturers work to reduce energy consumption and meet sustainability targets, attention is expanding beyond core production processes to the utility systems that support manufacturing. Steam systems, which play a critical role in sterilization, heating, and HVAC operations, can account for a significant share of a facility's energy consumption. Yet things like manual inspection practices and undetected steam trap failures often leave manufacturers with unnecessary energy losses, higher emissions, and increased operating costs. In this episode of Off Script, sponsored by Emerson, we spoke with Tom Belling, global director of Life Sciences at Emerson, about the growing role utilities play in pharmaceutical sustainability strategies, and the significance of steam systems within that. The conversation explores why steam systems have become an important opportunity for improving operational efficiency and how continuous monitoring technologies are helping manufacturers identify failures earlier without disrupting operations. Belling also discusses how wireless sensing, acoustic monitoring, and data-driven maintenance can improve reliability, support sustainability, and reduce maintenance costs while protecting product quality.
Not good news: Bugs are disappearing. Your windshield is way cleaner than it used to be. Hosts Kat and Tiff explore the different factors on why insect decline is happening, along with the (very scary) link between insect decline and food security. Listen to get answers to these questions:Why are insects disappearing? Why do we need insects?What would happen if insects went instinct? What can we do about it?SourcesNPR: https://www.npr.org/2025/09/12/nx-s1-5535551/insect-populations-human-interference-studyFriends of the Mississippi River: https://fmr.org/updates/conservation/why-insects-matter-and-what-you-can-do-about-their-declinePenn State Huck Institute of Life Sciences: https://www.huck.psu.edu/institutes-and-centers/insect-biodiversity-center/why-we-need-insectsOklahoma State Extension: https://extension.okstate.edu/fact-sheets/beneficial-insectsHuck Institute (again): https://www.huck.psu.edu/institutes-and-centers/insect-biodiversity-center/helping-insectsUC IPM: https://ipm.ucanr.edu/bee-precaution-pesticide-ratings/#gsc.tab=0Patreon: patreon.com/greeningupmyactInstagram: @greeningupmyactFacebook: Greening Up My ActEmail us with questions: greeningupmyact@gmail.comYouTube: Greening Up My Act
Sesh looks like a consumer brand. 8VC looks like the last fund that would back it. That mismatch is the fastest way to see what Austin is becoming.Sesh founder Max Cunningham and 8VC's Jake Medwell start with the logic that makes the deal make sense. Sesh holds a legal moat most competitors can't cross for years, and it earns software-like margins on a physical product. From there the conversation opens into a bigger question about where ambitious companies belong, and why more of them are choosing a city that now draws the founders and families betting on that future.Agenda00:00 What Sesh is06:05 Why 8VC backed a nicotine company10:44 Regulatory timing and the six-year door16:37 Software margins and owning the factory22:01 Who buys this and why the market is growing29:27 Why some companies need SF and others do not34:32 What Austin talent looks like now42:10 The Elon spillover and the coming IPO wave 48:37 Raising kids in the AI age55:07 Safety, schools, and what comes nextGuest LinksSesh: Max Cunningham, Website, X, Instagram8VC: Jake Medwell, Website, X -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack
In this episode of Tiny Matters, a listener who works in a pathology lab explains how even the ickiest specimens become ho-hum with time, sending Sam and Deboki down a rabbit hole of pathology history and the bizarre life of Rudolf Virchow, the “father of pathology” who was also rumored to have brought worm-filled sausages to a duel. Then, a listener's sourdough experiments spark a conversation about yeast and how these microscopic organisms are the chemists behind tasty bread, beer, wine, and more.We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
After nearly three years of sluggish job growth, hiring is turning a corner in the U.S. life sciences industry, while the talent pool is expanding beyond the sector's traditional hubs. On a special episode of the BioCentury This Week podcast, Ian Anderson, senior director, head of U.S. life sciences & healthcare research at CBRE, joins BioCentury's analysts to discuss the company's recent report on life sciences talent trends, and how those trends are driving property demand. This episode of the BioCentury This Week podcast has been brought to you by CBRE.View full story: https://www.biocentury.com/article/660118#LifeSciences #BiotechJobs #Workforce #LifeSciencesRealEstate #Talent00:01 - Sponsor Message: CBRE00:45 - Industry Inflection Point04:17 - Report Methodology10:08 - Growth Beyond Big Hubs15:28 - Capital Markets Signals18:48 - AI and Space Use20:50 - Emerging Talent26:34 - Up-and-Coming CitiesTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text
Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
What does it take to move a medical device from an idea to a solution that reaches patients? In this episode, Edwin Lindsay (Medtech's Guinness Guy) shares how 20+ years in medical devices shaped his hands-on approach to helping startups overcome regulatory, quality, and clinical challenges. He discusses why innovators need more than advice—they need experienced partners who help make decisions, execute strategies, and accelerate progress. Edwin also explores the hurdles facing pediatric device innovation and how his personal connection to the field inspired his mission to support founders and build stronger networks for life-changing technologies.Edwin Lindsay LinkedInCS Life Sciences WebsiteDuane Mancini LinkedInProject Medtech WebsiteProject Medtech LinkedInThank you to our sponsors: Ward Law, Wheelhouse DMG, and JumpStart Inc.
By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha MuruganWilfrid Laurier UniversityLife Science Editors FoundationJEDI ProgramScience Advances paper on limb regenerationFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In an AI-driven market, technology may be easier to replicate, but the right people remain a true competitive advantage. In this episode, Mike Silverstein, Managing Partner of Healthcare IT and Life Sciences at Direct Recruiters, discusses what healthcare companies often get wrong when building their teams. He explains why leaders should value grit over impressive résumés, how passive candidates can strengthen an organization, and why healthcare requires patience, resilience, and industry understanding. Mike also shares how beginning his recruiting career during the 2008 financial crisis helped him develop the relationships and determination needed to navigate future challenges. He emphasizes that lasting success comes from authenticity, meaningful networks, and consistently putting people first. Tune in to learn how healthcare organizations can build teams capable of thriving through uncertainty, technological change, and continued industry disruption. Resources Connect with Mike Silverstein on LinkedIn. Follow Direct Recruiters on LinkedIn and explore their website. Email Mike at mike@directrecruiters.com
In this episode of #CannabisUnlocked, Tiby Erdely sits down with Frederico Gomes of ATB Cormark Capital Markets to discuss why this moment in cannabis feels materially different than prior reform cycles - and why investors may finally be approaching a new institutional capital cycle.Frederico has covered the cannabis sector for more than seven years across U.S. MSOs, Canadian LPs, retailers, and ancillary operators. Having lived through the 2019 boom, a brutal bear market, and multiple federal reform false starts, he brings a seasoned perspective on what is real, what remains uncertain, and what could drive the next major leg of value creation.Fred and Tiby dive into the rapidly developing Schedule III rescheduling process, the potential timing and structure of a final rule, and why the biggest risks may be delay, litigation, and implementation - not whether cannabis ultimately moves forward. Fred explains how rescheduling could lower the cost of capital, improve cash flow, support institutional re-entry, and create a clearer path for industry leaders to emerge.The conversation then turns to valuations, uplisting, consolidation, SAFER Banking, and the rumored hemp ban. Fred discusses why many operators still trade at distressed multiples despite improving catalysts, and why exchange uplistings, cheaper capital, and limits on intoxicating hemp could drive sales growth, pricing stability, margin expansion, and renewed M&A.In closing, Tiby and Fred shift to Canada and the global cannabis opportunity, including how Canadian operators have evolved after their own boom-and-bust cycle, why Germany and international exports have become major growth drivers, and how U.S. operators may eventually participate in global markets. With rescheduling hearings underway, SAFER Banking back in the conversation, intoxicating hemp under pressure, Canadian names moving, and institutional investors beginning to revisit the sector, this episode captures one of the most important cannabis inflection points in years.Enjoy!
Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
© 2020-2026 Ivy Podcast Discovery LLC
